open access

Vol 5, No 1 (2002)
Published online: 2002-01-17
Submitted: 2012-01-23
Get Citation

Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125. Preliminary results

Zbigniew Wygoda, Rafał Tarnawski, Luther Brady, Zenon Stęplewski, Piotr Bażowski, Maciej Wojtacha, Tomasz Stępień, Dorota Kula, Kszysztof Składowski, Danuta Kokocińska, Andrzej Wygoda, Agnieszka Pawlaczek, Aleksandra Etmańska, Dawid Larysz, Barbara Jarząb
Nucl. Med. Rev 2002;5(1):29-33.

open access

Vol 5, No 1 (2002)
Published online: 2002-01-17
Submitted: 2012-01-23

Abstract

BACKGROUND: In this paper we present the preliminary results of a prospective trial of the efficacy of simultaneous radiotherapy and anti-EGFR 125I radioimmunotherapy of malignant gliomas with 2 years’ total survival as the end-point, raising the question whether anti-EGFR 125I radioimmunotherapy influences the disease-free survival in these patients.
MATERIAL AND METHODS: Patients with anaplastic astrocytoma or primary glioblastoma were previously treated by a macroscopically radical neurosurgical approach and randomized either to radiotherapy + radioimmunotherapy arm or treated by radiotherapy alone. Seven patients were included in the group with radioimmunotherapy, among them five with GBM and two with AA, and five patients in the control arm. Patients were irradiated to 60 Gy using three-dimensional conformal noncoplanar techniques. Anti-EGFR 125I monoclonal antibody 425 radioimmunotherapy (50 mCi/course) was started during 4th week of radiotherapy and was repeated three times in one week intervals.
RESULTS: Time of follow-up ranges between 2 and 10 months in the anti-EGFR 125I radioimmunotherapy arm and 4 and 9 months in the control arm. Recurrence was diagnosed in all patients in the EGFR 125I group with a lethal outcome in two of them and in 4 patients in the control group. Median time to recurrence was 2 and 5 months respectively.
CONCLUSIONS: Taking into account early recurrences observed, we propose to continue the studies on the efficacy of adjuvant anti-EGFR 125I radioimmunotherapy in a selected group of patients in whom the greatest benefit may be expected on the basis of molecular studies, among them EGFR expression investigation.

Abstract

BACKGROUND: In this paper we present the preliminary results of a prospective trial of the efficacy of simultaneous radiotherapy and anti-EGFR 125I radioimmunotherapy of malignant gliomas with 2 years’ total survival as the end-point, raising the question whether anti-EGFR 125I radioimmunotherapy influences the disease-free survival in these patients.
MATERIAL AND METHODS: Patients with anaplastic astrocytoma or primary glioblastoma were previously treated by a macroscopically radical neurosurgical approach and randomized either to radiotherapy + radioimmunotherapy arm or treated by radiotherapy alone. Seven patients were included in the group with radioimmunotherapy, among them five with GBM and two with AA, and five patients in the control arm. Patients were irradiated to 60 Gy using three-dimensional conformal noncoplanar techniques. Anti-EGFR 125I monoclonal antibody 425 radioimmunotherapy (50 mCi/course) was started during 4th week of radiotherapy and was repeated three times in one week intervals.
RESULTS: Time of follow-up ranges between 2 and 10 months in the anti-EGFR 125I radioimmunotherapy arm and 4 and 9 months in the control arm. Recurrence was diagnosed in all patients in the EGFR 125I group with a lethal outcome in two of them and in 4 patients in the control group. Median time to recurrence was 2 and 5 months respectively.
CONCLUSIONS: Taking into account early recurrences observed, we propose to continue the studies on the efficacy of adjuvant anti-EGFR 125I radioimmunotherapy in a selected group of patients in whom the greatest benefit may be expected on the basis of molecular studies, among them EGFR expression investigation.
Get Citation

Keywords

radioimmunotherapy; monoclonal antibody 425; epidermal growth factor receptor; iodine 125; glioblastoma; anaplastic astrocytoma

About this article
Title

Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125. Preliminary results

Journal

Nuclear Medicine Review

Issue

Vol 5, No 1 (2002)

Pages

29-33

Published online

2002-01-17

Bibliographic record

Nucl. Med. Rev 2002;5(1):29-33.

Keywords

radioimmunotherapy
monoclonal antibody 425
epidermal growth factor receptor
iodine 125
glioblastoma
anaplastic astrocytoma

Authors

Zbigniew Wygoda
Rafał Tarnawski
Luther Brady
Zenon Stęplewski
Piotr Bażowski
Maciej Wojtacha
Tomasz Stępień
Dorota Kula
Kszysztof Składowski
Danuta Kokocińska
Andrzej Wygoda
Agnieszka Pawlaczek
Aleksandra Etmańska
Dawid Larysz
Barbara Jarząb

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl